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trimester of a twin pregnancy
To the Editor: Rituximab, a chimeric monoclonal
anti-CD20 antibody originally developed for the
therapy of B-cell malignancies, has recently been
suggested as an option for severe atopic dermatitis
(AD),1 particularly in patients with elevated levels of
total immunoglobulin E (IgE) and/or specific IgE to
environmental allergens.
We report a 30-year-old woman with allergic
rhinitis, asthma, and AD since childhood, which was
resistant to intensive topical therapy with steroids
and tacrolimus and oral antihistamines. She had
documented allergies to Dermatophagoides spp.,
latex, cow’s milk proteins, egg proteins, and
peaches. Serial total IgE levels in blood were con-
sistently [ 20000 kU/L (normal IgE range \ 100
kU/L). She had been previously treated with sys-
temic corticosteroids, cyclosporine, mycophenolate
mofetil, and psoralen plus ultraviolet A light photo-
therapy (PUVA), with inconsistent and temporary
results, and she continued to have persistent severe
disease. The physical examination revealed lesions
involving 80% of her total body surface area (TBSA).
Rituximab was then proposed to the patient, after
complement deficiency, immunoglobulin defi-
ciencies, and severe infection had been ruled out;
pregnancy was excluded by a negative immuno-
logic human chorionic gonadotropin test in urine
1 week before the infusion, because her last men-
struation had occurred 4 weeks earlier. A baseline
complete blood cell count, total IgE level, and B
lymphocyte count were obtained. Written informed
consent was signed by the patient. The treatment
schedule consisted of two intravenous infusions of
rituximab 1000 mg 2 weeks apart.1 However, before
the second infusion, a second pregnancy test
was performed, which was positive. The infusionwas canceled and the pregnancy was closely
monitored in a high-risk pregnancy unit. Obstetric
ultrasonographies placed the date of conception 13
days before the first infusion. At week 36 of an
uncomplicated pregnancy, two healthy monozy-
gotic twins were delivered via cesarean section.
Our patient had a significant decrease in her IgE
levels (4000 kU/L) and TBSA decreased to 5% after
the single rituximab infusion; during the 17-month
follow-up period she did not experience new flares
of her dermatitis and no adverse events occurred.
Her closely monitored 8-month-old boys are grow-
ing and developing normally; careful hematologic
and immunologic monitoring has revealed no ad-
verse effects resulting from exposure to rituximab
(B lymphocyte levels of 1250/L and 1050/L for
each twin, respectively; IgA, IgM, IgG, and IgE
levels are normal in both twins).
Data regarding the use of rituximab during preg-
nancy are scarce and have been limited to patients
with hematologic disease: non-Hodgkin lym-
phoma,2 B-cell lymphoma,3 Burkitt lymphoma,4
acute thrombotic thrombocytopenic purpura,5 auto-
immune hemolytic anemia,6 and idiopathic throm-
bocytopenic purpura.7 In all reported cases, no
abnormalities have been found in fetal or child
development with the weekly regimen of 375
mg/m2 given as four to six infusions. Furthermore,
some have suggested that rituximab therapy for
lymphomas is a viable option for deferring cytotoxic
therapy early during pregnancy and might help to
reduce the risk of fetal malformation or abortion.4
Because AD is a chronic, nonfatal, inflammatory
disease, it is difficult to support its use in pregnant
women, regardless of the riskebenefit ratio.
Nonetheless, the present case is a valuable contri-
bution in asserting the safety of the drug in this
setting.
The significant and long lasting clinical improve-
ment produced in our patient with the single infu-
sion administered suggests that rituximab may be a
promising therapy in AD. Its administration during
pregnancy appears to be safe for the child, but
further studies are warranted.
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patient with psoriasis treated with
cyclosporine
To the Editor: In July 2008, a 60-year-old man who
had had psoriasis since 28 years of age presented
to our department with erosive lesions on the oral
and genital mucosa and erosive bullous lesions on
the skin, predominantly on the back and chest.
The lesions had arisen at a time when his psori-
asis had regressed almost completely, with few
residual erythematous, finely scaling lesions on
scalp and elbows. The patient had been on
continuous cyclosporine therapy (initial dosage,
250 mg/day) for his psoriasis for the previous 9
months. When he came to us, the cyclosporine
dose had been decreased to 140 mg/day and he
was using no topical treatment. The patient also
had congenital deaf-mutism and diabetes mellitus,
for which he had been taking glimepiride for
several years.
A biopsy specimen of an erosive lesion showed
suprabasal acantholysis on routine histology, IgG
and C3 deposits in intercellular spaces on direct
immunofluorescence, and antiedesmoglein 3 anti-
bodies (protein index value: 68 IU) found after anenzyme-linked immunosorbent assay led to a di-
agnosis of pemphigus vulgaris. The patient was
started on prednisone 60 mg/day; the cyclosporine
was tapered over 2 weeks and was replaced with
azathioprine (100 mg/day). Rapid clearing of the
erosive bullous lesions enabled gradual tapering of
the steroid. Eight months later, the patient con-
tinues on prednisone 15 mg/day and azathioprine
50 mg/day. Two mild episodes of pemphigus
exacerbation have been treated with higher steroid
doses. Slight worsening of the psoriasis related to
steroid tapering has been controlled with topical
treatment.
Reports of bullous disorders arising in psoriatic
patients are numerous and include predominantly
bullous pemphigoid1 and, among the intraepithe-
lial forms, pemphigus foliaceus.2 Various mecha-
nisms have been invoked to explain these
associations. An independent trigger of the bullous
disease has been identified in some cases (eg,
ultraviolet irradiation from phototherapy and pho-
tochemotherapy3), including drugs—particularly
penicillamine2 and enalapril4—and even irritant
topical antipsoriatic treatment, such as dithranol
and salicylic acid.3 However, removal of the suspi-
cious triggering agent in such cases rarely resolves
the bullous disease, especially when systemic drugs
are implicated.4 In the other cases, the trigger tends
to be the promoter of the bullous disease, which
then develops autonomously. Another mechanism
invoked to explain these associations is a genetic
predisposition.5 Nonetheless, a number of other
cases have no apparent explanation. Several re-
searchers have made reference to the epitope
spreading phenomenon,1 the hyperactivated im-
munologic status found in psoriatic patients,1 or the
molecular mimicry phenomenon, which may result
from acute or chronic infections.2 However, these
authors also suggest that the association of pem-
phigus and psoriasis may be a coincidence. A
meticulous search for a trigger in our patient,
including those mentioned above, was negative.
A role for the antidiabetic treatment was excluded.
Steroid treatment rapidly cleared his pemphigus
lesions, although there was a mild exacerbation of
his psoriasis associated with tapering of the steroid
dose.
The onset of pemphigus vulgaris despite the
immunosuppressant regimen was remarkable and
might not be a coincidence. It is possible that the
bullous disease may have been triggered by the
patient’s psoriasis and mediated by unknown mech-
anisms that overcame the effects of his iatrogenic
immunosuppressed status.
